CLINICAL TRIALS PROFILE FOR MYAMBUTOL

All Clinical Trials for MYAMBUTOL

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00002343 ↗	A Study of Rifabutin, Used Alone or With Ethambutol in the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in Patients With AIDS	Completed	Pharmacia	Phase 4	1969-12-31	To optimize Mycobacterium avium Complex (MAC) prophylaxis in AIDS patients by measuring serum rifabutin levels and adjusting the dose accordingly. To combine rifabutin with ethambutol to examine the effect of combination therapy in preventing or delaying the incidence of MAC bacteremia in this patient population.
NCT00864383 ↗	Controlled Comparison of Two Moxifloxacin Containing Treatment Shortening Regimens in Pulmonary Tuberculosis	Completed	Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma	Phase 3	2008-01-01	REMoxTB is a study for the "Rapid Evaluation of Moxifloxacin in the treatment of sputum smear positive tuberculosis". REMoxTB aims to find and evaluate new drugs and regimens that shorten the duration of tuberculosis therapy. The purpose of REMoxTB is to evaluate the efficacy, safety and acceptability of two moxifloxacin-containing treatment combinations to determine whether substituting ethambutol with moxifloxacin in one combination, and/or substituting isoniazid with moxifloxacin in another combination, makes it possible to reduce the duration of treatment for TB.
NCT00864383 ↗	Controlled Comparison of Two Moxifloxacin Containing Treatment Shortening Regimens in Pulmonary Tuberculosis	Completed	European and Developing Countries Clinical Trials Partnership (EDCTP)	Phase 3	2008-01-01	REMoxTB is a study for the "Rapid Evaluation of Moxifloxacin in the treatment of sputum smear positive tuberculosis". REMoxTB aims to find and evaluate new drugs and regimens that shorten the duration of tuberculosis therapy. The purpose of REMoxTB is to evaluate the efficacy, safety and acceptability of two moxifloxacin-containing treatment combinations to determine whether substituting ethambutol with moxifloxacin in one combination, and/or substituting isoniazid with moxifloxacin in another combination, makes it possible to reduce the duration of treatment for TB.
NCT00864383 ↗	Controlled Comparison of Two Moxifloxacin Containing Treatment Shortening Regimens in Pulmonary Tuberculosis	Completed	Sanofi	Phase 3	2008-01-01	REMoxTB is a study for the "Rapid Evaluation of Moxifloxacin in the treatment of sputum smear positive tuberculosis". REMoxTB aims to find and evaluate new drugs and regimens that shorten the duration of tuberculosis therapy. The purpose of REMoxTB is to evaluate the efficacy, safety and acceptability of two moxifloxacin-containing treatment combinations to determine whether substituting ethambutol with moxifloxacin in one combination, and/or substituting isoniazid with moxifloxacin in another combination, makes it possible to reduce the duration of treatment for TB.

Clinical Trial Conditions for MYAMBUTOL

Condition Name

Condition Name for MYAMBUTOL
Intervention	Trials
Pulmonary Tuberculosis	3
Tuberculosis	2
Mycobacterium Infections, Nontuberculous	1
Nontuberculous Mycobacterium Infection	1

Condition MeSH

Condition MeSH for MYAMBUTOL
Intervention	Trials
Tuberculosis	5
Mycobacterium avium-intracellulare Infection	3
Tuberculosis, Pulmonary	3
Mycobacterium Infections	3

Clinical Trial Locations for MYAMBUTOL

Trials by Country

Trials by Country for MYAMBUTOL
Location	Trials
United States	45
France	8
India	5
South Africa	5
Italy	4

Trials by US State

Trials by US State for MYAMBUTOL
Location	Trials
Colorado	3
Texas	3
California	3
Florida	2
District of Columbia	2

Clinical Trial Progress for MYAMBUTOL

Clinical Trial Phase

Clinical Trial Phase for MYAMBUTOL
Clinical Trial Phase	Trials
Phase 4	2
Phase 3	3
Phase 2/Phase 3	1

Clinical Trial Status

Clinical Trial Status for MYAMBUTOL
Clinical Trial Phase	Trials
Completed	5
Recruiting	3
Active, not recruiting	1

Clinical Trial Sponsors for MYAMBUTOL

Sponsor Name

Sponsor Name for MYAMBUTOL
Sponsor	Trials
Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma	1
Temple University	1
University of Colorado, Denver	1

Sponsor Type

Sponsor Type for MYAMBUTOL
Sponsor	Trials
Other	52
Industry	4
NIH	2